DermaSensor raises USD 16m in Series B funding round

DermaSensor Secures $16M to Scale AI-Powered Skin Cancer Detection in Primary Care

DermaSensor Inc., a medical device technology company transforming skin cancer detection for frontline care, today announced it has raised $16 million in Series B funding to fuel the commercial expansion of its FDA cleared, non-invasive skin cancer detection solution. This latest round of financing comprises most major existing investors, as well as new institutional investors including Pier 70 Ventures, Kern Venture Group, GenHenn Capital, and an undisclosed strategic investor. This additional $16M in capital brings the total investment in the company to $43 million.